Li Wenqiang, Li Mei, Huang Qian, He Xiaoyu, Shen Chen, Hou Xiaoming, Xue Fulai, Deng Zhiping, Luo Yao
Zigong First People's Hospital, Zigong, Sichuan, China.
West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Chem. 2023 Sep 7;11:1251986. doi: 10.3389/fchem.2023.1251986. eCollection 2023.
Lung cancer (LC) is one of the leading causes of high cancer-associated mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common type of LC. The mechanisms of NSCLC evolution involve the alterations of multiple complex signaling pathways. Even with advances in biological understanding, early diagnosis, therapy, and mechanisms of drug resistance, many dilemmas still need to face in NSCLC treatments. However, many efforts have been made to explore the pathological changes of tumor cells based on specific molecular signals for drug therapy and targeted delivery. Nano-delivery has great potential in the diagnosis and treatment of tumors. In recent years, many studies have focused on different combinations of drugs and nanoparticles (NPs) to constitute nano-based drug delivery systems (NDDS), which deliver drugs regulating specific molecular signaling pathways in tumor cells, and most of them have positive implications. This review summarized the recent advances of therapeutic targets discovered in signaling pathways in NSCLC as well as the related NDDS, and presented the future prospects and challenges.
肺癌（LC）是全球癌症相关高死亡率的主要原因之一。非小细胞肺癌（NSCLC）是LC最常见的类型。NSCLC演变的机制涉及多个复杂信号通路的改变。即使在生物学认识、早期诊断、治疗以及耐药机制方面取得了进展，NSCLC治疗仍面临许多困境。然而，人们已做出许多努力，基于特定分子信号探索肿瘤细胞的病理变化以进行药物治疗和靶向递送。纳米递送在肿瘤诊断和治疗方面具有巨大潜力。近年来，许多研究聚焦于药物与纳米颗粒（NPs）的不同组合以构建基于纳米的药物递送系统（NDDS），这些系统递送调节肿瘤细胞中特定分子信号通路的药物，并且其中大多数具有积极意义。本综述总结了NSCLC信号通路中发现的治疗靶点以及相关NDDS的最新进展，并阐述了未来前景和挑战。
